|
1.
|
|
12 p, 2.5 MB |
Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice
/
Galindo Campos, Miguel A. (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Lutfi, Nura (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Bonnin, Sarah (Centre de Regulació Genòmica) ;
Martínez Cáceres, Carlos (Instituto Murciano de Investigación Biosanitaria-Laboratorio de Investigación Biosanitaria-Arrixaca) ;
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García-Hernández, Violeta (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Martín Caballero, Juan (Instituto Cajal. Consejo Superior de Investigaciones Científicas (CSIC)) ;
Ampurdanés, Coral (Cancer Research Program. Hospital del Mar Medical Research Institute (IMIM)) ;
Gimeno, Ramón (Laboratory of Immunology. Department of Pathology) ;
Colomo, Lluís (Hospital del Mar (Barcelona, Catalunya)) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Guilbaud, Guillaume (Division of Protein and Nucleic Acid Chemistry. Medical Research Council Laboratory of Molecular Biology) ;
Dantzer, Françoise (Biotechnology and Cell Signaling. Unité Mixte de Recherche (UMR) 7242 Centre National de la Recherche Scientifique. Laboratory of Excellence Medalis. École Supérieure de Biotechnologie de Strasbourg. Strasbourg University) ;
Navarro, Pilar (Hospital del Mar Medical Research Institute. Unidad Asociada IIBB-CSIC) ;
Murga, Matilde (Genomic Instability Group. Spanish National Cancer Research Centre) ;
Fernández Capetillo, Oscar (Science for Life Laboratory. Department of Medical Biochemistry and Biophysics. Karolinska Institutet) ;
Bigas Salvans, Anna (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sale, Julian E. (Division of Protein and Nucleic Acid Chemistry. Medical Research Council Laboratory of Molecular Biology) ;
Yélamos, José (Laboratory of Immunology. Department of Pathology)
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. [...]
2022 -  10.1182/blood.2021012805
Blood, Vol. 139 Núm. 2 (13 2022) , p. 228-239
|
|
|
2.
|
|
15 p, 3.1 MB |
Peptides against Low Density Lipoprotein (LDL) Aggregation Inhibit Intracellular Cholesteryl Ester Loading and Proliferation of Pancreatic Tumor Cells
/
Benitez Amaro, Aleyda (Institut d'Investigacions Biomèdiques de Barcelona) ;
Martínez-Bosch, Neus (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Manero-Rupérez, Noemí (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Claudi, Lene (Institut d'Investigacions Biomèdiques de Barcelona) ;
La Chica Lhoëst, Maria Teresa (Institut d'Investigacions Biomèdiques de Barcelona) ;
Soler Castany, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Ros-Blanco, Lia (Institut d'Investigació Biomèdica Sant Pau) ;
Navarro, Pilar (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Llorente-Cortés, Vicenta (Institut d'Investigació Biomèdica Sant Pau)
Dyslipidemia, metabolic disorders and/or obesity are postulated as risk factors for pancreatic ductal adenocarcinoma (PDAC). The majority of patients with these metabolic alterations have low density lipoproteins (LDLs) with increased susceptibility to become aggregated in the extracellular matrix (ECM). [...]
2022 - 10.3390/cancers14040890
Cancers, Vol. 14 Núm. 4 (February 2022) , p. 890
|
|
|
3.
|
|
7 p, 1.1 MB |
Prognostic impact of CD133 expression in Endometrial Cancer Patients
/
Mancebo, Gemma (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Sole-Sedeno, J. M. (Hospital del Mar (Barcelona, Catalunya)) ;
Pino, O. (Universitat Pompeu Fabra) ;
Miralpeix, E. (Hospital del Mar (Barcelona, Catalunya)) ;
Mojal, S. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Garrigós Cubells, Laia (Vall d'Hebron Institut d'Oncologia) ;
Lloveras, B. (Hospital del Mar (Barcelona, Catalunya)) ;
Navarro, Pilar (Institut d'Investigacions Biomèdiques de Barcelona) ;
Gibert, J. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Lorenzo, M. (Hospital del Mar (Barcelona, Catalunya)) ;
Aran Ballesta, Iris (Hospital del Mar (Barcelona, Catalunya)) ;
Carreras, Ricard (Hospital del Mar (Barcelona, Catalunya)) ;
Alameda, Francesc (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques)
To assess the impact of CD133 expression on the prognosis of endometrioid endometrial carcinoma (EEC). We retrospectively assessed CD133 expression in tissue microarray of 116 surgically treated FIGO I-III EEC. [...]
2017 - 10.1038/s41598-017-08048-0
Scientific reports, Vol. 7 (august 2017)
|
|
|
4.
|
|
17 p, 2.8 MB |
Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis
/
Martínez Bosch, Neus (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Cristóbal, Helena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Iglesias, Mar (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Gironella, Meritxell (Hospital Clínic i Provincial de Barcelona) ;
Barranco, Luis E (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Visa, Laura (Hospital del Mar (Barcelona, Catalunya)) ;
Calafato, Domenico (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Jiménez-Parrado, Silvia (Centro Nacional de Investigaciones Oncológicas) ;
Earl, Julie (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Carrato, Alfredo (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Manero-Rupérez, Noemí (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Moreno Merino, Mireia (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Morales, Albert (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Guerra, Carmen (Centro Nacional de Investigaciones Oncológicas) ;
Navarro, Pilar (Institut d'Investigacions Biomèdiques de Barcelona) ;
García de Frutos, Pablo (Institut d'Investigacions Biomèdiques de Barcelona)
Early diagnosis is crucial for patients with pancreatic ductal adenocarcinoma (PDAC). The AXL receptor tyrosine kinase is proteolytically processed releasing a soluble form (sAXL) into the blood stream. [...]
2021 - 10.1016/j.ebiom.2021.103797
EBioMedicine, Vol. 75 (december 2021)
|
|
|
5.
|
|
13 p, 2.1 MB |
Increased plasma levels of galectin-1 in pancreatic cancer : potential use as biomarker
/
Martinez-Bosch, Neus (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Barranco, Luis E. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Orozco, Carlos A. (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Moreno, Mireia (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Visa, Laura (Hospital del Mar (Barcelona, Catalunya)) ;
Iglesias, Mar (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Oldfield, Lucy (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ;
Neoptolemos, John P. (Department of General Surgery, University of Heidelberg, Heidelberg, Germany) ;
Greenhalf, William (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ;
Earl, Julie (Hospital Universitario Ramón y Cajal (Madrid)) ;
Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Costello, Eithne (Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK) ;
Navarro, Pilar (Institut d'Investigació Biomèdica Sant Pau)
Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. [...]
2018 - 10.18632/oncotarget.26034
Oncotarget, Vol. 9 (august 2018) , p. 32984-32996
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
